Clinical Therapeutics/New Technology-Pharmacological Treatment of Complications

Clinical Therapeutics/New Technology-Pharmacological Treatment of Complications

Open Access
Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?
Ele Ferrannini, Julio Rosenstock

Diabetes Care Mar 2021, 44 (3) 641-646; DOI: 10.2337/dc20-0913
Open Access
Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis
David C. Klonoff, Jordan C. Messler, Guillermo E. Umpierrez, Limin Peng, Robby Booth, Jennifer Crowe, Valerie Garrett, Raymie McFarland, Francisco J. Pasquel

Diabetes Care Feb 2021, 44 (2) 578-585; DOI: 10.2337/dc20-1857
You have access
Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion
Carolina Solis-Herrera, Giuseppe Daniele, Mariam Alatrach, Christina Agyin, Curtis Triplitt, John Adams, Rupal Patel, Amalia Gastaldelli, Henri Honka, Xi Chen, Muhammad Abdul-Ghani, Eugenio Cersosimo, Stephano Del Prato, Ralph DeFronzo

Diabetes Care May 2020, 43 (5) 1065-1069; DOI: 10.2337/dc19-2177
You have access
Pharmacist-Provided Diabetes Education and Management in a Diverse, Medically Underserved Population
Kristina Wood Naseman, Andrew S. Faiella, Garrett M. Lambert

Diabetes Spectrum May 2020, 33 (2) 210-214; DOI: 10.2337/ds19-0048
Open Access
Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming
Angelo Avogaro, Gian Paolo Fadini, Stefano Del Prato

Diabetes Care Mar 2020, 43 (3) 501-507; DOI: 10.2337/dc19-1410
Open Access
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Lindsay E. Clegg, Hiddo J.L. Heerspink, Robert C. Penland, Weifeng Tang, David W. Boulton, Srinivas Bachina, Robert D. Fox, Peter Fenici, Marcus Thuresson, Robert J. Mentz, Adrian F. Hernandez, Rury R. Holman

Diabetes Care Feb 2019, 42 (2) 318-326; DOI: 10.2337/dc18-1871
Open Access
Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial
Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, Hiroki Teragawa, Yosuke Okada, Kosuke R. Shima, Toshinari Takamura, Isao Taguchi, Itaru Hisauchi, Shigeru Toyoda, Yasushi Matsuzawa, Hirofumi Tomiyama, Minako Yamaoka-Tojo, Hisako Yoshida, Yasunori Sato, Yumi Ikehara, Shinichiro Ueda, Yukihito Higashi, Koichi Node

Diabetes Care Oct 2019, 42 (10) e159-e161; DOI: 10.2337/dc19-1177
You have access
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Fernando Bril, Diane M. Biernacki, Srilaxmi Kalavalapalli, Romina Lomonaco, Sreevidya K. Subbarayan, Jinping Lai, Fermin Tio, Amitabh Suman, Beverly K. Orsak, Joan Hecht, Kenneth Cusi

Diabetes Care Aug 2019, 42 (8) 1481-1488; DOI: 10.2337/dc19-0167
Open Access
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, Khalid Jamal Farooqui, Manish Kumar Singh, Jasjeet Singh Wasir, Beena Bansal, Parjeet Kaur, Ganesh Jevalikar, Harmendeep Kaur Gill, Narendra Singh Choudhary, Ambrish Mithal

Diabetes Care Aug 2018, 41 (8) 1801-1808; DOI: 10.2337/dc18-0165
Open Access
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
Michaël J.B. van Baar, Charlotte C. van Ruiten, Marcel H.A. Muskiet, Liselotte van Bloemendaal, Richard G. IJzerman, Daniël H. van Raalte

Diabetes Care Aug 2018, 41 (8) 1543-1556; DOI: 10.2337/dc18-0588

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Pharmacological Treatment of Complications

Pages

Navigate

More Information

Other ADA Resources